Signs of T-cell Lymphoma

Dave Coulier Reveals 2nd Cancer Diagnosis in a Year

Dave Coulier reveals new cancer diagnosis, 7 months after beating lymphoma

A little over a year after being diagnosed with non-Hodgkin lymphoma, Dave Coulier announced exclusively on the "TODAY" show that he is undergoing treatment for an unrelated tongue cancer.

· 1d

Dave Coulier Announces 2nd Cancer Diagnosis After Beating Non-Hodgkin Lymphoma

· 1d

Dave Coulier says he is fighting another form of cancer, months after beating lymphoma

· 1d

Dave Coulier Says He’s Battling New Cancer After Beating Lymphoma

Dave Coulier, known for his role as Uncle Joey on “Full House,” announced on Tuesday that he is battling a new cancer, just seven months after sharing he had beaten non-Hodgkin lymphoma.

· 1d

What Type of Cancer Does Dave Coulier Have? Breaking Down the ‘Full House’ Alum’s New Diagnosis

IJR · 1d

‘Full House’ Star Reveals 2nd Cancer Diagnosis

· 1d

‘Full House’ star Dave Coulier reveals new cancer diagnosis months after beating lymphoma

“The silver lining here is that I had cancer, which helped me detect my other cancer.

AARP · 1d

‘Full House’ Star Dave Coulier Opens Up About Life After Two Cancer Diagnoses

· 1d

‘Full House’ star diagnosed with new cancer 7 months after beating Lymphoma

MedPage Today

'Armored' CAR T Cells Highly Active in Lymphoma After Prior CAR-T Failure

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9.6 months, with some responses lasting more than 2 years.

Medscape

NICE Approves CAR T-Cell Therapy for Patients With Lymphoma

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays disease progression and improves survival outcomes.

Pharmabiz

EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma

EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma: Lund, Sweden Tuesday, November 18, 2025, 11:00 Hrs [IST] BioInvent In